GlioCure strengthens its management team with the recruitment of Dr. Sandrine Courtès as Director of Preclinical Development and Intellectual Property
GlioCure SA, a biotechnology company specializing in neuro-oncology, announces the arrival of Dr. Sandrine Courtès, a researcher-entrepreneur dedicated to brain... View Article
InFlectis BioScience licenses rights to a potential new class of therapies for demyelinating diseases from the University of Chicago
InFlectis BioScience has been granted exclusive patent rights from the University of Chicago to use a family of small molecules for the treatment... View Article
Jessica Walker has been elected Board Member of the Council of European Bioregions!
Atlanpole Biotherapie’s European project manager Jessica Walker has been elected Board Member of the Council of European Bioregions! This European... View Article
Oncology: infrared light could help surgeons see more clearly the tumors during operations
The University Medical Center Groningen and Kaer Labs announce entering into a research collaboration to evaluate NIR-II fluorescence for biological... View Article
New partner | 2 do it
Engaged in relational performance in business, Lucie Léger strongly believes that we can transform businesses and employees ! Reinvent relational... View Article
New partner | SinnRJ
SinnRJ’s core activity is to support innovative structures (SMEs, large groups, academic laboratories) in obtaining regional, French and especially European... View Article
New partner | Strategiqual
Strategiqual is a leading consultancy organization highly skilled for drugs, medical devices and in vitro medical devicesprojects. Strategiqual provides companies... View Article
New partner | Alison Munro
25+ years dedicated to Health innovation. Founded Alison Munro Corporate Language (AMCL) in 2005. Has coached 350+ startups & top-notch... View Article
Valneva completes recruitment for Phase 3 Lot-to-Lot Consistency Trial of its Chikungunya Vaccine Candidate
Valneva, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet... View Article
Valneva completes Phase 3 trial recruitment for its inactivated COVID-19 vaccine candidate
Valneva , a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant... View Article